Antiplatelet for Coronary Artery Disease in Specific Condition “No Size Fits All”

Author(s): Benny M. Setiadi, Beny Hartono, Adhitia B. Prakoso, Anggia C. Lubis, Reza M. Munandar, Muhammad Munawar*.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 4 , 2018


Antiplatelet is the cornerstone therapy for patient with coronary artery disease. Several comorbidities can influence the efficacy and safety of antiplatelet agent. Diabetes mellitus is characterized by increased platelet reactivity and reduced response to antiplatelet. Elderly patients have both reduced response to antiplatelet and increased risk of bleeding. Patients with renal dysfunction also had decreased efficacy of antiplatelet accompanied with increased risk of bleeding. In patients with atrial fibrillation, the concomitant use of anticoagulant with antiplatelet poses an increased risk of bleeding. In patients with these comorbidities, caution should be stressed in selecting the best regimen of antiplatelet which translates the most optimal efficacy while minimizing the risk of adverse events. In this review, we will discuss the platelet changes in these comorbidities, current evidence of antiplatelet usage in these group of patients and current recommendation.

Keywords: Antiplatelet, coronary artery disease, diabetes mellitus, elderly, renal dysfunction, atrial fibrillation.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [478 - 495]
Pages: 18
DOI: 10.2174/1381612824666180209111212
Price: $58

Article Metrics

PDF: 22
PRC: 1